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Abstract
Rotavirus (RV) is the leading cause of infantile gastroenteritis worldwide. RV nonstructural protein 4 (NSP4), the first characterized viral
enterotoxin, is a 28-kDa glycoprotein that has pleiotropic functions in RV infection and pathogenesis. NSP4 has multiple forms enabling it to
perform its different functions. Dissecting such functions could be facilitated by use of epitope-specific antibodies. This work mapped the epitopes
for the monoclonal antibody B4-2/55 and three polyclonal antisera generated against synthetic SA11 NSP4 peptides corresponding to residues
114–135, 120–147, and 150–175. The epitope for B4-2/55 mapped to residues 100–118, wherein residues E105, R108 and E111 are critical for
antibody binding. Antiserum generated to two peptides (aa114–135 and aa120–147) with enterotoxin activity each recognize a single but distinct
epitope. The epitope for the peptide antiserum to aa114–135 was mapped to residues 114–125 with highly conserved residues T117/T118, E120,
and E122 being critical for antibody binding. The peptide antiserum to aa120–147 binds to NSP4 at residues 130–140 and residues Q137–T138
are critical for this epitope. Finally, the epitope for the antiserum to peptide aa150–175 mapped to residues 155–170, wherein residues E160 and
E170 are critical for antibody binding. Knowledge of the binding sites of domain-specific antibodies can aid in further characterizing different
functions of NSP4. To demonstrate this, we characterized the interaction between NSP4 and VP5⁎ [KD=0.47 μM] and show that binding of NSP4
to VP5⁎ is blocked by antibody to NSP4 aa114–135 and aa120–147, but not aa150–175. The use of single epitope-specific antibodies to
differentially block functions of NSP4 is a feasible approach to determine the functional domain structure of this important RV virulence factor.
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Rotaviruses (RV) are complex, glycosylated but non-
enveloped viruses. The RV genome consists of 11 segments
of double-stranded RNA that code for six structural and six
nonstructural proteins (Estes and Kapikian, 2007). RV is the
leading etiological agent of severe gastroenteritis in infants and
young animals worldwide, which leads to the hospitalization of
1 in 60 children in the United States and approximately 600,000
fatalities worldwide (Fischer et al., 2007; Parashar et al., 2003).
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doi:10.1016/j.virol.2007.11.021protein 4 (NSP4), which is a pleiotropic protein involved in
many aspects of RV infection including being the first
characterized viral enterotoxin (Ball et al., 1996). NSP4 is
initially produced in the endoplasmic reticulum (ER) as a
transmembrane glycoprotein with high mannose carbohydrate
moieties on amino acids (aa) 8 and 18 (Ericson et al., 1983b,a).
Intracellularly expressed NSP4 causes an increase in the levels
of intracellular calcium, which in-turn influences vesiculation of
NSP4 and the association of NSP4-containing vesicles with
viroplasms (Berkova et al., 2006). NSP4 also serves as an
intracellular receptor for VP6 on newly formed double-layered
particles (DLPs) (Au et al., 1993; Berkova et al., 2006; Meyer
et al., 1989). In a morphological process unique to RV, nascent
DLPs bud into the lumen of the ER, with particles acquiring a
transient envelope as well as the outer coat protein VP7 and the
spike protein VP4 (Petrie et al., 1983; Tian et al., 1996).
212 J.M. Hyser et al. / Virology 373 (2008) 211–228Through an uncharacterized mechanism that involves NSP4 and
VP7, the envelope is lost and VP4 and VP7 are retained to
generate the mature virion (Cuadras et al., 2006; Lopez et al.,
2005; Poruchynsky and Atkinson, 1991).
In addition to its role in RV morphogenesis, NSP4 is the only
characterized viral enterotoxin (Ball et al., 1996; Jagannath
et al., 2006; Mori et al., 2002; Sasaki et al., 2001; Zhang et al.,
2000). From the ER, NSP4 traffics to the plasma membrane via
a non-classical, Golgi-independent route. NSP4 is cleaved by a
still uncharacterized protease and a C-terminal cleavage product
is released from the infected cell (Zhang et al., 2000). This
cleavage product consists of aa112–175 and contains the
enterotoxin domain (aa114–135), which stimulates a phospho-
lipase C-mediated Ca2+ mobilization and age-related Cl−
secretion from neonatal but not adult intestinal cells. This is
thought to be the mechanism behind the age-dependent diarrhea
caused by NSP4 (Ball et al., 1996; Dong et al., 1997; Morris
et al., 1999).
NSP4 is found in multiple forms. Several studies, including
three crystal structures, indicate that NSP4 forms oligomers,
including dimers, tetramers, and larger oligomers (Bowman
et al., 2000; Deepa et al., 2007; Jagannath et al., 2006; Taylor
et al., 1998). Computational and biochemical analyses indicate
an extended coiled-coil domain from amino acids 85–135
directs the formation of NSP4 tetramers, but both hydrophobic
(aa24–46) and amphipathic alpha helical (aa55–85) domains as
well as the C-terminus (aa146–175) contribute to the formation
of large aggregates of NSP4 (Jagannath et al., 2006; Lin and
Tian, 2003). Further, NSP4 is found in multiple cellular
compartments, as well as in viroplasms, and a cleavage product
is released extracellularly (Berkova et al., 2006; Parr et al.,
2006; Sapin et al., 2002; Zhang et al., 2000). Several cellular
protein-binding sites have been mapped to the NSP4 cytoplas-
mic tail (Ball et al., 2005). The binding sites for the RV spike
protein VP4 and intermediate capsid protein VP6 have been
mapped to NSP4 aa112–148 and aa161–175, respectively (Au
et al., 1993; O'Brien et al., 2000). The multitude of NSP4 forms
and functions requires highly specific reagents to differentiate
between various forms of NSP4 and determine the functional
significance of a given form.
This manuscript reports the mapping of four epitope-specific
antibodies to the NSP4 cytoplasmic tail: monoclonal antibody
(MAb) B4-2/55 and antisera generated to synthetic NSP4
peptides corresponding to aa114–135 (αNSP4114–135), aa120–
147 (αNSP4120–147), and aa150–175 (αNSP4150–175). For each,
residues that are critical for the binding of the antibody to NSP4
were identified. The utility of these antibodies was demon-
strated by characterizing the interaction between NSP4 and the
VP4 spike protein, which is blocked by antibodies specific for
the enterotoxin domain.
Results
Mapping MAb B4-2/55
Previously published immunoelectron microscopy (IEM)
data of thin sections of rotavirus-infected cells and immuno-precipitation of NSP4 transcribed in vitro in the presence of
microsomes using MAb B4-2/55 suggested that the epitope
recognized by this MAb is found on the long cytoplasmic
C-terminus of NSP4, which corresponds to amino acids 47–175
(Au et al., 1993; Petrie et al., 1984). To further map MAb B4-2/
55, a series of N- and C-terminal truncation constructs of NSP4
were constructed in a bacterial expression plasmid with an N-
terminal 6×-histidine tag. A schematic of the His-tagged
truncation proteins and summary of their reactivities with
MAb B4-2/55 is illustrated in Fig. 1. This summary is based on
Western blot analysis of the purified His-tagged NSP4
truncations using either MAb B4-2/55 (Figs. 2A and C),
polyclonal αNSP4-FL (Figs. 2B and D), or by Ponceau S
staining to demonstrate equal protein loading (Figs. 2A–D,
lower panels). B4-2/55 failed to recognize NSP4105–175 and
NSP4112–175 N-terminal truncations (Fig. 2A, lanes 5–6) and a
NSP475–116 C-terminal truncation (Fig. 2C, lane 9). The positive
control αNSP4-FL serum recognized all of the truncation
products as expected (Figs. 2B and D). These data confirm that
B4-2/55 detects a linear epitope within amino acids 100–118 of
NSP4 (Fig. 3D).
Group A rotavirus NSP4 sequences cluster into 5 distinct
genogroups (Ciarlet et al., 2000; Lin and Tian, 2003) and
monoclonal antibody B4-2/55 was generated against the human
rotavirus Wa, which has a genogroup B NSP4. We sought to
determine the cross-reactivity of B4-2/55 against each NSP4
genogroup as one approach to identify residues potentially
critical for B4-2/55 binding to NSP4. The reactivity of B4-2/55
was examined by Western blot with lysates from MA104 cells
infected with SA11 Cl. 3 (genogroup A), OSU (genogroup B),
RRV (genogroup C), ECTC (genogroup D), or Ty-1 (genogroup
E) or mock-infected cells. Reactivity was also tested with an
aliquot of each lysate treated with endoglycosidase H (Endo H)
to remove the carbohydrates followed byWestern blotting using
either MAb B4-2/55 or a rabbit antiserum to a NSP4 peptide
(aa113–149) as a positive control (Figs. 2E and F). Western blot
analysis using the rabbit anti-NSP4 peptide 113–149 showed
that SA11 cl. 3 NSP4 in the Endo H-treated and untreated lysates
migrates at the expected 20 kDa and 28 kDa, respectively
(Fig. 2F). The 113–149 peptide antiserum reacted with each
NSP4 from genogroups A–D very well, although the apparent
molecular sizes of the proteins differed slightly (identified by
black dots). This antiserum also weakly detected Ty-1 NSP4.
The weak reactivity of this antiserum against Ty-1 NSP4 is not
surprising, given the greater genetic distance between SA11 and
Ty-1 compared with the other RV strains used. Both the rabbit
anti-NSP4 peptide 113–149 serum and MAb B4-2/55 reacted
with SDS-PAGE resistant oligomers as well as bands that
migrated faster than the unglycosylated 20 kDa NSP4, which are
likely cleavage products of NSP4. Western blot analysis using
MAb B4-2/55 showed reactivity with both glycosylated and
unglycosylated NSP4 from genogroupsA–D; however, B4-2/55
did not react with Ty-1 (genogroup E) NSP4 (Fig. 2E). Based on
these results, we hypothesized that residues critical for B4-2/55
binding to NSP4 should be relatively well conserved among
mammalian rotavirus NSP4s but not conserved in the avian
NSP4 sequences.
Fig. 1. Schematic diagram of truncation constructs of SA11 NSP4. A linear diagram of full-length NSP4 is shown at the top, numbers indicating the corresponding
amino acid position. The 3 hydrophobic domains (boxes), glycosylation sites (straight lines), and ER membrane domains (curved lines) are shown. The truncation
constructs generated are illustrated below and aligned corresponding to the full-length protein. The name of each construct is listed to the left of the illustration and all
have an N-terminal 6×His-tag (black box). A summary of the reactivity of MAb B4-2/55, αNSP4114–135, αNSP4120–147 (Figs. 2 and 4C, respectively) by Western blot
is listed to the right of illustration where + indicates reactivity, − indicates no reactivity, ND indicates not done, and (+) indicates reactivity but the data is not shown.
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not genogroup E (Fig. 2E), we hypothesized that critical residues
should be relatively well conserved between genogroups A–D,
but differ when compared to genogroup E. A multiple sequence
alignment (Fig. 3A) illustrating amino acids 100, 104, 105, 107,
108, 111, 112, 115, and 118 shows non-conservative changes
(underlined bold font) that differ between genogroup A and
genogroup E and are the most likely candidates to be the critical
residues of the B4-2/55 epitope. The importance of these resi-
dues for B4-2/55 binding was tested by introducing single ala-
nine substitution mutations at these positions in the NSP490–175
truncation construct background.Western blot analysis (Fig. 3B,
left) of these mutants using MAb B4-2/55 showed that B4-2/55
detected both monomer and oligomer of NSP490–175 D100A,
K104A, R107A, M112A, and T117A/T118A. In contrast, B4-2/55 failed to detect the monomer of NSP490–175 E105A, R108A,
and E111A. Interestingly, B4-2/55 detected the SDS-resistant
oligomer of these mutants, though the detection of the E105A,
R108A, and E111A oligomer was weaker than that of WT
NSP490–175. B4-2/55 did not detect the monomer and oligomer
of the triple mutant (E105A/R108A/E111A) suggesting that
ablation of B4-2/55 binding to NSP4 requires mutation of at least
two of these residues. All of the mutants were detected by
αNSP4-FL (Fig. 3B, right). There appeared to be less of the
dimeric and trimeric oligomers for the E111A and M112A
proteins despite similar protein loading (Fig. 3B, Ponceau S).
Yet, since the alanine substitutions are detected by the polyclonal
antiserum, the mutations only changed the local structure of the
B4-2/55 epitope, but did not perturb the overall structure of
NSP4.
Fig. 2. Epitope mapping of B4-2/55. A–D: Immunoblot analysis of NSP4 truncation constructs. N- or C-terminal trunctions of NSP4 were expressed in BL21(DE3)
E. coli and purified on Ni-NTA beads. Purified protein separated by SDS-PAGE and blotted onto nitrocellulose was stained with Ponceau S to confirm equal loading
(lower panels). Duplicate blots were reacted with either MAb B4-2/55 (A and C) or mouse anti-NSP4-FL (B and D). E and F: Genogroup cross-reactivity of B4-2/55.
MA104 cells were either mock- or rotavirus-infected with a MOI of 1 for SA11 cl. 3 (genogroup A), OSU (genogroup B), RRV (genogroup C), ECTC (gengroup D), or
Ty-1 (gengroup E) and maintained for 48 h. at 37 °C. Cells were lysed in RIPA buffer and separated by SDS-PAGEwithout and with Endo H treatment for 2 h at 37 °C,
as indicated by and, respectively. Arrows (left of each blot) indicate the fully glycosylated ∼28 K (upper) and non-glycosylated ∼20 K (lower) NSP4, and the black
dots indicate these two main forms for each strain. Cleavage products were present in all cell lysates. Identical blots were incubated with either MAb B4-2/55 (E) or
rabbit anti-NSP4 peptide 113–149 (F).
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E111 are critical for recognition of the NSP4 monomer by B4-2/
55; however, mutation of any one of these residues alone
weakened, but did not ablate, detection of the NSP4 oligomer.
The stronger detection of the NSP4 oligomer than the monomer
by B4-2/55 suggested that there may be additional contacts
between B4-2/55 and oligomeric NSP4 that are lost by
denaturing NSP4 into a monomer. This led us to question if
the B4-2/55 epitope was conformational, rather than linear,
since for some proteins elements of secondary structure remain
stable under SDS-PAGE conditions and conformational epi-
topes are detected by Western blot analysis (Parker et al., 2005;
Zhou et al., 2007).We tested if E105, R108, and/or E111 were also critical for
the detection of native NSP4 by determining the end-point titer
of B4-2/55 against each of the mutant constructs by ELISA
(Fig. 3C). For the ELISA, NSP490–175 and NSP4105–175 were
used as positive and negative controls, respectively. The end-
point titer for B4-2/55 for alanine substitution mutants of D100,
K104, R107, or M112 was not statistically different than that of
wild-type NSP490–175. In contrast, mutation of E105A, R108A,
E111A, or all three amino acids in the triple mutant resulted in a
statistically significant reduction in the end-point titer. This
assay allowed us to assign a relative importance of each residue
for binding by B4-2/55, such that E105≅R108NE111, since
both E105A and R108A exhibited a similarly reduced end-point
Fig. 3. Identification of residues critical for B4-2/55 binding. A: Multiple sequence alignment of NSP4 representing each genogroup. Primary NSP4 sequence
corresponding to amino acids 99–119 for SA11 cl. 3 (genogroup A), Wa-attenuated (genogroup B and the immunogen for B4-2/55), OSU (genogroup B), RRV
(genogroup C), ECTC (gengroup D) and Ty-1 (genogroup E) are shown. The B4-2/55 epitope (aa100–118) is highlighted in bold type on the SA11 cl. 3 sequence.
Conservative changes relative to SA11 NSP4 are shown in bold type, and non-conservative changes are in underlined bold type. Residues that differ between
genogroups A–D and genogroup E within the B4-2/55 epitope are indicated by arrows. B: Immunoblot analysis of alanine substitution mutants. Alanine mutants of
NSP490–175 were expressed in BL21(DE3) E. coli, purified by Ni–NTA beads, separated by SDS-PAGE, blotted onto nitrocellulose, and stained by Ponceau S to
determine equal loading (lower panels). Identical blots were detected with either MAb B4-2/55 or αNSP4-FL. Arrows indicate NSP4 monomers or oligomers in the
immunoblot. C: ELISA end-point titer of B4-2/55 against NSP4 alanine mutants. ⁎ indicates pb0.01 by Students T-test. D: The SA11 NSP4 sequence is shown
highlighting the B4-2/55 epitope (aa100–118) in bold with the critical residues (105, 108, and 111) underlined.
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(6400). Thus, B4-2/55 binds to the oligomerization domain of
NSP4 within aa100–118, residues E105, R108, and E111 are
critical for the interaction between B4-2/55 and either native or
denatured NSP4, and mutation of these residues individually
reduces the strength of the interaction but does not eliminate it.
αNSP4114–135 and αNSP4120–147 detect distinct NSP4 epitopes
The two enterotoxic peptides (synthetic SA11 NSP4 peptides
aa114–135 and aa120–147) used to generate two antisera differ
only slightly in their sequence; however, previous studies usingthese two peptide-specific antisera suggested that αNSP4114–135
and αNSP4120–147 reacted to distinct epitopes on NSP4 (unpub-
lished data). To determine the epitopes for the two antisera, we
performed dot blot analysis to test their reactivities with three
synthetic peptides, which correspond to NSP4 aa113–149,
aa114–135, and aa120–147, respectively (Fig. 4A). The
synthetic peptides were spotted onto nitrocellulose membranes
and detected with either αNSP4114–135 or αNSP4120–147. The
peptide aa113–149, which encompasses both of the other pep-
tide sequences, was used as a positive control and was detected
by both antisera (Fig. 4B). In contrast, the αNSP4114–135 only
detected the aa114–135 peptide and not the aa120–147 peptide,
Fig. 4. Mapping the epitopes for αNSP4114–135 andαNSP4120–147. A: Sequence alignment and summary of the αNSP4114–135 and αNSP4120–147 reactivity to the SA11
NSP4 synthetic peptides used in the dot blot analysis (shown in B). + indicates reactivity and − indicates no reactivity. B: The synthetic peptides indicated on the top
of the blots were spotted onto nitrocellulose and reacted with the antibody indicated to the right of the blot. C: Immunoblot analysis of NSP4 truncation constructs. N- or
C-terminal trunctions of NSP4 were expressed in BL21(DE3) E. coli and purified on Ni–NTA beads. Purified protein separated by SDS-PAGE and blotted onto
nitrocellulose was stained with Ponceau S to confirm equal loading (lower panels). Duplicate blots were reacted with either αNSP4114–135 (left) or mouse αNSP4120–147
(right). D: The SA11 NSP4 aa113–149 sequence highlighting the distinct epitopes detected by αNSP4114–135 (aa114–125—single underline) and αNSP4120–147
(aa130–140—double underline).
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and αNSP4120–147 are each specific for distinct epitopes within
aa113–149.
The minimal binding sequence for these two peptide antisera
was further defined by Western blot analysis using αNSP4114–135
(Fig. 4C, left), αNSP4120–147 (Fig. 4C, right). Ponceau S staining
of each blot demonstrated equal protein loading for each of the N-
and C-terminal NSP4 truncations (Fig. 4C, lower panels). The
truncations used and summary of the antibody reactivities are
shown in Fig. 1. αNSP4114–135 detected C-terminal trun-
cations NSP475–146 (lane 2) through NSP475–130 (lane 5), weakly
detected NSP475–125 (lane 6), but was unable to or only faintly
detected NSP475–120 or NSP475–118. This antiserum was also
unable to detect the N-terminal truncation NSP4130–175 (lanes
7–9). αNSP4120–147 was only able to detect NSP475–146 and
NSP475–140 (lanes 2 and 3), but not the otherC-terminal truncations
(lanes 4–8). NSP4130–175 was detected by αNSP4120–147 (lane 9).
Based on theWestern blot analysis, theminimal binding sequences
for αNSP4114–135 and αNSP4120–147 were NSP4 aa114–125
and aa130–140, respectively. Thus, the differential detection of the
N- and C-terminal truncations by these two antisera supports the
dot blot data and indicates that αNSP4114–135 and αNSP4120–147
are each specific for distinct epitopes (Fig. 4D, underlined).Mapping the critical residues of αNSP4114–135
The epitope detected by αNSP4114–135 falls within a highly
conserved domain of NSP4 that includes the putative calcium
binding site (aa120–123)which is 100% conserved in all GroupA
RV NSP4 sequences (Fig. 5A). Thus, as expected, αNSP4114–135
detected NSP4 from six different rotavirus strains: SA11 (simian),
S2 (human), Ala (lapine), C-11 (lapine), Ito (human), and RRV
(simian) using Western blot analysis of infected cell lysates
(Fig. 6A, right upper panel). To determine the amino acid residues
within this epitope that are critical for the antibody–antigen
interaction, we again utilized alanine substitution mutations of the
HisNSP490–175 construct. Based on the sequence conservation of
the putative calcium binding site, we focused the mutagenesis on
this motif and adjacent residues, and the purified His-tagged
mutants were analyzed by Western blot analysis using
αNSP4114–135 (Fig. 5B, left), αNSP4120–147 (Fig. 5B, middle),
and αNSP4-FL (Fig. 5B, right). Mutation of T117/T118, E120, or
E122 to alanine eliminated the detection of the NSP490–175
monomer by αNSP4114–135; however, weak detection of the
oligomer was seen for the T117A/T118A and E120A mutants.
Mutation of R119, Q123, or LL126/127 had no effect on
detection. Interestingly, αNSP4114–135 showed stronger detection
Fig. 5. Identification of the critical residues of the αNSP4114–135 epitope. A: Multiple sequence alignment of the NSP4 sequence from aa113–149 for SA11, S2, Ala,
C-11, Ito, and RRV. The αNSP4114–135 epitope (aa114–125) is underlined in the SA11 sequence and residues 100% conserved in all Group A RV NSP4 sequences
are highlighted by bold font. B: Immunoblot analysis of alanine substitution mutants. Alanine mutants of NSP490–175 were expressed in BL21(DE3) E. coli, purified
by Ni–NTA beads, separated by SDS-PAGE, blotted onto nitrocellulose, and stained by Ponceau S to determine equal loading (lower panel). Identical blots were
detected with αNSP4114–135 (left), αNSP4120–147 (middle), or αNSP4-FL (right). Arrows indicate NSP4 monomers or oligomers in the immunoblot. C: The SA11
NSP4 sequence is shown, highlighting the αNSP4114–135 epitope (aa114–125) in bold with the important residues (117, 118, 120, and 122) underlined and the critical
E122 indicated by the asterisk (⁎).
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especially since the relative amount of the monomer was greater
than the oligomer as detected by Ponceau S. This bias for detec-
tion of the oligomer is not apparent for either αNSP4120–147 or
αNSP4-FL. Thesemutations do not disrupt the overall structure of
NSP4, since both αNSP4120–147 and αNSP4-FL detected WT
and mutant NSP4 similarly. Thus, while residue E122 was critical
for detection of NSP4 by αNSP4114–135, mutation of T117/T118
or E120 reduced detection of NSP4 suggesting these residues
are also important for this epitope (Fig. 5C).
Mapping the critical residues of αNSP4120–147
We next sought to further map the epitope detected by
αNSP4120–147. The Western blot analysis of truncation con-
structs (Fig. 4C, right) indicated the epitope fell between aa130
and 140, which is a region of NSP4 that shows sequence
diversity between rotavirus strains. To identify candidate resi-
dues critical for the detection of NSP4 by αNSP4120–147, we
tested the reactivity of this antiserum against NSP4 from lysates
of the six different rotavirus strains previously discussed. An
alignment of the amino acid sequence for the six NSP4s and
immunoblot analysis of the lysates is shown in Fig. 6A. Im-munoblot analysis showed that while αNSP4114–135 detected
NSP4 from all six rotavirus strains, αNSP4120–147 only detected
SA11 NSP4. By comparing the sequences in Fig. 6A we
predicted that the critical residues for this epitope are T135,
Q137 and/or T138 because αNSP4120–147 is unable to detect S2
NSP4 and those residues are the only changes between the S2
and SA11 NSP4 sequences.
We investigated the importance of these three residues by
testing the reactivity of αNSP4120–147 against various synthetic
NSP4 peptides, listed in Fig. 6B. These peptides represent either
the SA11 or S2 amino acid sequence as well as substitution of
one or two residues (Fig. 6B, left). The peptides were resolved
on a Tris–Tricine SDS-polyacrylamide gel and blotted onto a
nitrocellulose membrane and then detected with αNSP4120–147
(Fig. 6B, right). The αNSP4120–147 serum detected the SA11
peptide (lane 2), but not the S2 peptide (lane 6). The Q137R
mutation completely abolished detection of this peptide by
αNSP4120–147 (lane 3), indicating that Q137 is critical for
antibody binding.Mutation of T138S (lanes 4 and 5) reduced the
level of detection by αNSP4120–147, suggesting that T138 is also
important for antibody binding, yet the conservative change
from threonine to serine weakened, but did not abolish, antibody
binding. In contrast, the T135I mutation did not affect the level
Fig. 6. Identification of the critical residues for the αNSP4120–147 epitope. A: Multiple sequence alignment of the NSP4 sequence from aa113–149 for SA11, S2, Ala,
C-11, Ito, and RRV (left) and immunoblot analysis of RV infected lysates of the above strains (right). The αNSP4120–147 epitope (aa130–140) is underlined in the SA11
sequence and residues hypothesized as critical for the αNSP4120–147 epitope are highlighted by bold font. Individual blots were detected by either αNSP4114–135 or
αNSP4120–147. Arrows indicate the nonglycosylated (lower) and glycosylated (upper) NSP4 bands. B: Amino acid sequence alignment (left) and immunoblot (right) of
synthetic NSP4 peptides from aa128–140. Residues identified as critical for αNSP4120–147 are highlighted by bold and underlined font. The immunoblot was detected
by αNSP4120–147. C: Immunoblot analysis of alanine substitution mutants. Alanine mutants of NSP490–175 were expressed in BL21(DE3) E. coli, purified by Ni–NTA
beads, separated by SDS-PAGE, and blotted onto nitrocellulose. Identical blots were detected with αNSP4120–147 (left), αNSP4150–175 (middle), or αNSP4-FL (right).
D: The SA11 NSP4 sequence is shown, highlighting the αNSP4120–147 epitope (aa130–140) in bold with the critical residues (137 and 138) underlined.
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antibody binding. To confirm the peptide blot results, alanine
mutation of residues Y131, T135, Q137, and T138 were
generated in HisNSP490–175 and analyzed by immunoblot as
before. Purified His-tagged NSP4 mutants were detected with
αNSP4120–147 (Fig. 6C, left), αNSP4150–175 (Fig. 6C, middle),
and αNSP4-FL (Fig. 6C, right). αNSP4120–147 detected Y131A
and T135A mutants similar to WT NSP490–175, but mutation of
Q137 or T138 to alanine abolished detection of NSP4. These
mutations did not disrupt the overall structure of NSP490–175
because both αNSP4150–175 and αNSP4-FL detected all mutant
constructs to similar levels. Thus, the epitope for αNSP4120–147
falls between amino acids 130–140 and Q137 and T138 are
critical residues for antibody binding (Fig. 6D).Mapping αNSP4150–175
Lastly, we used similar methods to map a peptide-specific
antibody to NSP4 aa150–175. As before, we utilized the
naturally occurring sequence divergence within this region of
NSP4 to identify the epitope and potentially critical residues for
the αNSP4150–175 antiserum. Fig. 7A shows a multiple
sequence alignment for NSP4 aa150–175 and corresponding
immunoblot analysis of infected cell lysates of the six RV
strains used previously and αNSP4114–135 was used as the
positive control. αNSP4150–175 detected NSP4 from SA11, S2,
Ala, Ito, had weak detection of C-11 NSP4, and no detection of
RRV NSP4. By comparing this profile with the multiple
sequence alignment (Fig. 7A), a number of changes between the
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the weaker detection of C-11 NSP4 compared to that of Ala
NSP4 suggested that the single amino acid change between
these two sequences, E170K, might be involved in antibody
binding. Additionally, there are numerous changes between the
detected NSP4s and RRV NSP4. These changes are N152Y,
V153F, E157N, E160A, S161E and K163E (using the SA11
and RRV sequences), and are highlighted by bold and un-
derlined fonts in the sequence alignment.
To furthermap theminimal binding sequence forαNSP4150–175
and determine which of these residues was critical for
αNSP4150–175 binding to NSP4, three nested sets of synthetic
peptides incorporating these changes were generated (Fig. 7B,
left). NSP4112–175 and NSP4112–150 were used as positive and
negative controls, respectively. Analysis of the synthetic pep-Fig. 7. Mapping and identification of critical residues for the αNSP4 150–175 epitop
SA11, S2, Ala, C-11, Ito, and RRV (left) and immunoblot analysis of RV infected ce
αNSP4150–175 epitope are highlighted by bold and underlined font. Individual blot
nonglycosylated (lower) and glycosylated (upper) NSP4 bands. B: Sequence alignm
aa150–175. Residues identified as critical for the αNSP4150–175 are highlighted b
C: Immunoblot analysis of alanine substitution mutants. Alanine mutants of NSP490–
by SDS-PAGE, and blotted onto nitrocellulose. Identical blots were detected with α
NSP4 sequence is shown, highlighting the αNSP4150–175 epitope (aa155–170) in botides indicated that αNSP4150–175 was unable to detect either
the SA11 peptide aa150–165 or the N152Y or V153F mutant
peptides (Fig. 7B, lanes 4–6). Peptides corresponding to SA11
NSP4 aa155–170 and aa160–175 were both detected (lanes 7
and 13) by the antiserum, suggesting that the minimal binding
sequence fall within residues 155–170. Amino acid changes of
S161E or K163E resulted in a slightly reduced detection of the
aa155–170 peptide by αNSP4150–175 (lanes 9–10). In contrast,
the changes of E160A (in peptide aa155–170) and E170K (in
peptide aa160–175) both dramatically reduced the detection of
the corresponding peptide by αNSP4150–175, suggesting that
these two residues are critical for antibody binding. As above,
the peptide blot results were confirmed by immunoblot analysis of
single alanine mutants of residues E160, K163, or E170 in the
HisNSP490–175 construct using αNSP4120–147 (Fig. 7C, left),e. A: Multiple sequence alignment of the amino acid sequence from 150–175 for
ll lysates from the above strains (right). Residues hypothesized as critical for the
s were detected by either αNSP4114–135 or αNSP4150–175. Arrows indicate the
ent (left) and immunoblot (right) of an array of synthetic NSP4 peptides from
y bold and underlined font. The immunoblot was detected by αNSP4150–175.
175 were expressed in BL21(DE3) E. coli, purified by Ni–NTA beads, separated
NSP4120–147 (left), αNSP4150–175 (middle), or αNSP4-FL (right). D: The SA11
ld with the critical residues (160 and 170) underlined.
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As with the peptide blot, mutation of E160 or E170 caused a loss
of NSP4 detection by αNSP4150–175, but the K163A mutant was
detected similar to wild-type NSP490–175. None of the mutants
affected the ability of αNSP4120–147 or αNSP4-FL to detect
NSP4, demonstrating that these mutants disrupt this epitope and
not the overall structure of NSP490–175. Thus, αNSP4150–175
binds to NSP4 within aa155–170 and E160 and E170 are critical
for antibody binding.
The binding of NSP4 to VP5⁎ is blocked by αNSP4114–135 and
αNSP4120–147
We hypothesize that the peptide-specific antisera are each
specific for a single epitope on NSP4, since the mutation of a
single critical residue within the epitope is sufficient to ablateFig. 8. The binding of NSP4 to VP5⁎ is blocked by αNSP4114–135 or αNSP4120–147,
response of the binding of increasing concentrations of NSP4-FL to HisVP5⁎ (A) or H
values are resonance units (RU) normalized to the maximum resonance units of NSP
the relative SPR response of the binding of increasing concentrations of SA11 NSP
detected in a control cell was subtracted. y axis values are resonance units (RU) norm
HisVP5⁎. D: An ELISA-based NSP4–VP5⁎ binding assay was used to test the abilit
interaction. The results are plotted as the percent NSP4 bound relative to the posit
(pb0.01, Students T-test) between the pre-immune serum and the NSP4-specific andetection of NSP4. Thus, the specificity of these antisera makes
them useful for the mapping and characterization of different
functional and protein–protein binding domains of NSP4, most
of which reside in the cytoplasmic tail. The RV spike protein
VP4 is one suggested NSP4 binding partner; however, this
interaction has not been investigated in detail (Au et al., 1993).
We used the antisera mapped above to further characterize the
interaction between NSP4 and VP4.
In order to show a direct interaction between NSP4 and VP4,
as well as to determine which proteolytic fragment of VP4
(either VP5⁎ or VP8⁎) binds to NSP4, we analyzed the binding
of untagged SA11 NSP4-FL to His-tagged VP5⁎ or VP8⁎ by
Surface Plasmon Resonance (SPR) using a BIAcore 3000
system. Various concentrations of SA11 NSP4-FL protein were
passed over flow cells of NTA sensor chips upon which
HisVP5⁎ (Fig. 8A) or HisVP8⁎ (Fig. 8B) had been immobilized.but not by αNSP4150–175. A and B: Representative profiles of the relative SPR
isVP8⁎ (B). Background binding detected in a control cell was subtracted. y axis
4-FL binding to HisVP5⁎ or HisVP8⁎, respectively. C: Representative profile o
4 peptide aa114–135 or peptide aa150–175 to HisVP5⁎. Background binding
alized to the maximum resonance units of NSP4 peptide aa114–135 binding to
y of αNSP4114–135, αNSP4120–147, and αNSP4150–175 to block the NSP4–VP5⁎
ive control (without antibody) versus the serum dilution. Statistical difference
tiserum was determined.f
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(Fig. 8A) but not HisVP8⁎ (Fig. 8B). The NSP4 site that binds
VP5⁎ was determined by testing the ability of synthetic NSP4
peptides corresponding to aa114–135 or aa150–175 to bind to
VP5⁎. Various concentrations of NSP4 aa114–135 and 1.6μM
NSP4 aa150–175 were passed over flow cells of a CM5 sensor
chip that had been chemically conjugated to HisVP5⁎ (Fig. 8C).
NSP4 aa114–135, but not NSP4 aa150–175 bound to VP5⁎,
confirming the previously published data that the VP4 binding
site on NSP4 mapped to the enterotoxin domain. The
dissociation constant (KD) for the interaction between NSP4-
FL or NSP4 aa114–135 and HisVP5⁎ was determined by
flowing increasing concentrations of NSP4-FL (0.38–6.0 μM)
and NSP4 aa114–135 (0.4–1.6 μM) over immobilized HisVP5⁎
and the KD calculated using a one-site-binding nonlinear
regression model. Both full-length NSP4 and aa114–135 of
NSP4 bound VP5⁎ with similar affinities (NSP4-FL-VP5⁎: KD
∼0.47±0.1 μM; aa114–135–VP5⁎: 0.43±0.28 μM).
Finally, an ELISA-based NSP4–VP5⁎ binding assay was
developed to test the ability of the three peptide-specific antisera
to block this interaction (Fig. 8D). Various concentrations of a
rabbit pre-immune serum (negative control), αNSP4114–135,
αNSP4120–147, or αNSP4150–175 were mixed with SA11 NSP4
and then added to VP5⁎-coated wells of a microtiter plate.
Bound NSP4 was detected by mouse αNSP4-FL antisera and a
HRP-conjugated secondary antibody. The positive control,
NSP4–VP5⁎ binding without antibody was set to 100%. The
data are expressed as percent of the positive control. Neither the
pre-immune sera, nor αNSP4150–175 significantly reduced the
binding of NSP4 to VP5⁎. In contrast, both αNSP4114–135 and
αNSP4120–147 significantly blocked the binding of NSP4 to
VP5⁎ (pb0.01) in a dose-dependent manner. Together, these
data show that the interaction between the enterotoxin domain
of NSP4 (aa114–140) and VP5⁎ is direct, strong, and specific.
Discussion
Identification of multiple and novel functions of NSP4 in RV
replication and pathogenesis has made this molecule a focus of
study. However, since NSP4 has multiple forms, occupies
several intracellular compartments and is released extracellu-
larly, it is challenging to specifically correlate a given form of
NSP4 to a distinct function (Ball et al., 2005). The ability of the
NSP4 cleavage product to elicit diarrhea as well as to induce an
immune response that is protective has made pursuit of the
immunological properties of NSP4 important (Choi et al.,
2005).
The work presented here describes the detailed mapping of
four epitope specific antibodies to the SA11 NSP4 cytoplasmic
tail. A summary (Fig. 9A) of the binding on a linear schematic
shows the epitopes and critical residues for the four antibodies
studied. Within each epitope we identified key residues im-
portant for antibody binding. It is possible that some of the key
residues identified are critical for the folding of the epitope, but
may not be directly involved in the antibody–antigen interac-
tion. However, this is unlikely to be the case for the following
reasons: [1] all of the antibodies had linear epitopes and de-tected denatured wild-type NSP4, thus protein folding should
not be a consideration. [2] For each epitope, alanine mutations
near the critical residues did not affect detection of NSP4 by the
corresponding antibody. [3] Mutation of residues critical for one
epitope, i.e. E122, did not affect detection of NSP4 by either
αNSP4-FL or the other epitope-specific antibodies, and [4]
analysis of wild-type NSP4 and the E120A and Q123A mutants
by circular dichroism showed no difference in secondary struc-
tural elements (data not shown). Thus, any alanine mutation in
our studies would only affect the structure of the epitope if it is
directly involved in the antibody–antigen interaction.
Each of these four antibodies has interesting properties that
will facilitate further characterization of the multifaceted NSP4
domain structure, illustrated in part by the crystal structure
shown in Fig. 9B (Bowman et al., 2000). The three epitopes
present within the crystal structure are tightly packed together,
with few, if any, residues between them. Given this tightly
packed yet distinct epitope structure, these antibodies can be
used to differentiate different forms of NSP4 and determine
which domains are present on a given form or intracellular pool
of NSP4. Further, it is possible that the overall epitope structure
is similar for NSP4 from other RV strains.
One previous study mapped epitopes of the pigeon rotavirus
PO-13 NSP4 by the production of MAbs to that protein (Borgan
et al., 2003). In those studies, the authors describe MAbs that
map to four antigenic sites, though the minimal binding
sequence was not determined. When aligned to the SA11
NSP4 sequence, the epitopes detected by 3 of the PO-13 MAbs
correspond to aa112–133, aa136–151, and aa155–175 and are
similar to the epitopes mapped in the current study for
αNSP4114–135, αNSP4120–147, and αNSP4150–175, respectively.
An epitope analogous to the B4-2/55 MAb epitope was not
isolated in the PO-13 MAb study; however, given the seeming
importance of the NSP4 oligomer for B4-2/55 binding, it is
tempting to speculate that this domain on avian NSP4 is less
immunogenic due to its lack of a coiled-coil domain (Lin and
Tian, 2003). Thus, while our peptide antisera were made to
synthetic peptides rather than full-length NSP4, it is compelling
that the overall epitope structure of the cytoplasmic tail is
similar for both SA11 NSP4 and PO-13 NSP4, suggesting that
similar domains of divergent NSP4s are immunogenic irre-
spective of the primary sequence. This idea lends credence to
the theory that NSP4 from divergent RV stains has evolved to
maintain a structure/function relationship, as suggested by the
biochemical and functional similarities between Group A and
Group C RV NSP4 proteins, in the absence of any significant
primary sequence conservation (Horie et al., 1997; Sasaki et al.,
2001). It would be interesting to extend these studies by
determining if Group C RV NSP4s has a similar epitope
structure.
There are a number of important differences between the
epitopes found in the PO-13 MAb study and the present work.
The PO-13 NSP4 MAb mapping to aa136–151 showed cross-
reactivity against NSP4 from all genogroups, despite this region
having high amino acid diversity. The corresponding antibody
described here, αNSP4120–147, showed the opposite phenotype,
as it was specific to SA11, whereas αNSP4114–135 had the
Fig. 9. Summary of the antibody mapping in the NSP4 cytoplasmic tail. A: Linear schematic diagram of the four epitope specific antibodies. The epitopes recognized
by the four antibodies are shown in the blue (B4-2/55), gold (αNSP4114–135), magenta (αNSP4120–147), and green (αNSP4150–175) boxes. The critical residues
identified for each are highlighted in red. B: Organization of the B4-2/55, αNSP4114–135 and αNSP4120–147 epitopes on the NSP4 crystal structure (PDB accession
number 1G1I; Bowman et al., 2000). Each epitope is color coded as above and the critical residues are highlighted in red. E105 is on the reverse face of the structure.
C: Localization of the critical residues on the NSP4 tetramer (PDB accession numbers 1G1I and 1G1J; Bowman et al., 2000). The critical residues are highlighted
according to their respective epitope as in A. D: Localization of the VP5⁎ binding domain on the tetramer structure of NSP495–137. The minimal VP5 binding site
(NSP4 aa114–135) is highlighted in green, while the DLP binding site is indicated by the blue box.
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αNSP4114–135 is likely due to the high degree of sequence
identity for this epitope across NSP4 genogroups, and two of the
critical residues (E120 and E122) are 100% conserved in all
reported sequences. In contrast, since few reported NSP4
sequences contain the Q137 residue, as does SA11 NSP4
(aa137 is K/R on most NSP4s), it is likely that αNSP4120–147
was specific to SA11 due to the glutamine 137 and did not react
with other NSP4s due to the difference in charge of this position.Since NSP4 forms oligomers, we also visualized the critical
residues for each epitope in the context of a tetramer (Fig. 9C). In
the tetramer, the residues critical for antibody binding to their
respective epitopes are clustered together and surface exposed.
For the B4-2/55 epitope, based on the multiple sequence
alignment (Fig. 3A) residue K115 was identified as a possible
candidate, but the alanine substitution of this residue was not
tested in this study. It seemed unlikely that K115 was involved in
the epitope, since it falls on the edge of the minimal binding
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nor T117A/T118A affected the detection of NSP4 by B4-2/55.
However, in the crystal structure K115 does cluster with E105,
R108, and E111 so it remains possible that this residue also
contributes to the interaction. In the αNSP4114–135 epitope,
residue E120, which contributes to the αNSP4114–135 epitope, is
only partially exposed and antibody binding may induce
localized conformational changes to expose E120. Both B4-2/
55 and αNSP4114–135 bind within the tetramerization coiled-coil
domain, and showed a biased detection of the SDS-resistant
NSP4 oligomers (Figs. 3B and 5B) over the monomer. This bias
was often more apparent for the point mutants that disrupted
antibody binding, since the oligomer but not the monomer was
detected. This led us to question whether or not the categoriza-
tion of these epitopes as linear was appropriate or if conforma-
tional elements of the epitope were assembled upon
oligomerization of NSP4. Both antibodies detected the dena-
tured monomeric form of wild-type NSP4 and the epitopes
contained 18 and 11 residues for B4-2/55 and αNSP4114–135,
respectively, suggesting that these are true linear epitopes.While
oligomerization is not essential for antibody binding, it appears to
enhance the affinity of the antibody–antigen interaction. This
suggests that the presentation of this epitope is slightly different
between the denatured monomer and oligomeric form or
additional bonds are present between the antibody and the
NSP4 oligomer that strengthen the overall affinity of the
interaction. The enhanced antibody binding afforded by NSP4
oligomerization partially compensated for the mutation of any
single, but not multiple, critical residues within the B4-2/55 and
αNSP4114–135 epitopes. Together, these data suggest that these
antibodies bind to the NSP4 oligomer with a higher affinity than
to the NSP4 monomer. Similar MAbs to the HIV envelope
protein have been characterized, indicating that B4-2/55 and
αNSP4114–135 recognize a novel type of linear epitope that is
sensitive to the quaternary structure of NSP4 (Broder et al., 1994;
Gorny et al., 2000).
This underscores the importance of oligomerization to the
structure and antigenicity of NSP4. Recent work to characterize
the biochemical mechanism of oligomerization of NSP4
suggests that the amphipathic alpha helical domain (aa55–
85), coiled-coil domain (aa95–137), and the C-terminus
(aa147–175) all contribute to the formation of NSP4 oligomers
and high molecular weight aggregates (Jagannath et al., 2006).
Despite much in vitro biochemical analysis of NSP4 oligomer-
ization, mutations that disrupt oligomer formation have not
been reported. Moreover, little is known about NSP4 oligomer-
ization during a RV infection. Given that B4-2/55 and
αNSP4114–135 have higher affinity for the NSP4 oligomer
than the monomer, it may be possible to use these antibodies to
differentially stain the NSP4 oligomer pool from the monomer
pool in RV-infected cells and determine if NSP4 oligomeriza-
tion is linked to the formation of the calcium-triggered NSP4
vesicules associated with viroplasms (Berkova et al., 2006).
In the recent crystal structures of bacterially expressed
NSP4 95–146, residues 138–146 are disordered, and larger
fragments of NSP4 containing either the amphipathic alpha
helix or the C-terminal 29 residues did not crystallize (Deepaet al., 2007). B4-2/55 and αNSP4114–135 may be useful for
screening conditions for the assembly of monodispersed NSP4
oligomers of larger fragments or full-length NSP4 that would be
more amenable to crystallization. Alternatively, co-crystallization
of NSP4 bound to the B4-2/55 Fab fragment may prevent the
formation of high molecular weight soluble aggregates of NSP4
(Jagannath et al., 2006). The use of Fab fragments ofαNSP4120–147
or αNSP4150–175–if they can be sufficiently purified–may force
the disordered residues of the NSP4 C-terminus into a more
ordered state that could be visualized in the crystal structure.
The detailed mapping of these antibodies to NSP4 will also
enable further dissection of NSP4 functional domains. Using the
NSP4 peptide specific antibodies, we characterized the interac-
tion between NSP4 and the RV spike protein VP4. Previous
studies have shown that NSP4 aa112–148 binds VP4. We have
refined this to show that the VP5⁎ fragment of the spike protein
binds NSP4 and aa114–135 are sufficient for binding. The
interaction is specific because αNSP4114–135 and αNSP4120–147
block binding, but αNSP4150–175 did not, confirming previous
data that the C-terminus is dispensable for the VP5⁎–NSP4
interaction (Au et al., 1993).
Multiple pools of VP4 and NSP4 have been described in RV-
infected cells, including a fraction of each that traffics to the
plasma membrane, and both proteins localize to detergent-
resistant rafts (Berkova et al., 2006; Cuadras et al., 2006; Sapin
et al., 2002; Storey et al., 2007). These two proteins might work
in concert to establish the non-classical, apically targeted release
of RV in polarized cells (Sapin et al., 2002). siRNA knock-down
or tunicamycin treatment of RV-infected cells, which affects the
production and maturation of NSP4, respectively, also blocked
the associated of VP4 with mature virions and detergent-
resistant rafts. Thus, the interaction between NSP4 and VP5⁎
appears to be critical for assembly of VP4 spikes during particle
formation in the ER (Cuadras et al., 2006). If VP4 has to be
assembled onto the DLP before VP7, as recently suggested, the
high affinity interactions between the entertoxin domain of
NSP4 (aa114–135) and VP5⁎ and the DLP binding domain of
NSP4 (aa161–175) and DLPs during particle maturation could
correctly orient the spike onto maturing particles before VP7
assembly, illustrated in Fig. 9D (Cuadras et al., 2006).
Lastly, since αNSP4150–175 binds to the extreme C-terminus
of NSP4, previously shown to bind nacent DLPs and facilitate
their budding into the ER, then use of αNSP4150–175 Fab
fragments to block the binding of NSP4 to DLPs may further
elucidate the mechanism for the NSP4–DLP interaction (Au
et al., 1993; Meyer et al., 1989; O'Brien et al., 2000). Addi-
tionally, αNSP4120–147 and αNSP4150–175 may block the
interaction between NSP4 and tubulin, reported to bind NSP4
aa120–175, further mapping and confirming the specificity of
NSP4–tubulin interaction (Xu et al., 2000).
In summary, our detailed epitope map of the SA11 NSP4
cytoplasmic tail using both MAb and epitope-specific peptide
antibodies supports a model of NSP4 in which distinct domains
are closely juxtaposed within the primary sequence yet they can
be distinguished by examining the global epitope structure of
the molecule. Mapping binding of the VP5⁎ fragment of the RV
spike to NSP4 aa114–135 by use of the antibodies characterized
Table 1
Primers for N- and C-terminal truncation constructs
Primer
name
Sequence
Fwda aa75 5′GACGACGACAAGATGATTTTTAATACGTTGTTAAAATTG
Fwd aa90 5′GACGACGACAAGATAACTACTAAAGATGAGATAG
Fwd aa95 5′GACGACGACAAGATAGAAAAGCAAATGGACAG
Fwd aa100 5′GACGACGACAAGATAGACAGAGTAGTCAAAGAAATG
Fwd aa105 5′GACGACGACAAGATAGAAATGAGACGCCAGCTAG
Fwd aa112 5′GACGACGACAAGATAATGATTGACAAATTGACTAC
Fwd aa130 5′GACGACGACAAGATGATTTACGATAAATTGACGGTGC
Revb aa175 5′GAGGAGAAGCCCGGTTTACATTGCTGCAGTCAC
Rev aa146 5′GAGGAGAAGCCCGGTTTATTTTGTCATATCTATTTCGCC
Rev aa140 5′GAGGAGAAGCCCGGTTTAGCCTGTCGTTTGCACCGT
Rev aa135 5′GAGGAGAAGCCCGGTTTACGTCAATTTATCGTAAATG
Rev aa130 5′GAGGAGAAGCCCGGTTTAAATGCGTTTAAGCAACTC
Rev aa125 5′GAGGAGAAGCCCGGTTTACTCTACTTGTTCAATTTC
Rev aa120 5′GAGGAGAAGCCCGGTTTATTCACGTGTAGTCAATTTG
Rev aa118 5′GAGGAGAAGCCCGGTTTATGTAGTCAATTTGTCAATC
Rev aa116 5′GAGGAGAAGCCCGGTTTACAATTTGTCAATCATTTC
Forward (Fwda) and reverse (Revb) primers are listed and numbered according
to the first or last NSP4 residue encoded, respectively. The underlined sequence
is added according to the manufacturer's protocol for the ligation-independent
cloning procedure.
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multifunctional NSP4 virulence factor.
Materials and methods
Cell lines and viruses
Simian SA11 clone 3 (cl. 3) (G3, P6[2]) and RRV (G3, P5B
[3]); human S2 (G2, P1B[4]) and Ito (G3, P1A[8]); lapine Ala
(G3, P11[14]) and C-11 (G3, P11[14]); porcine OSU (G5, P9
[7]); murine ECTC (G3, P[19]); and avian Ty-1 (G7, P[17])
rotavirus strains were propagated in the African Green Monkey
kidney cell line MA104 using DMEM supplemented with
trypsin (Worthington Biochemical Corporation, Lakewood, NJ)
as previously described (Ciarlet et al., 2002). The αNSP4
hybridoma cell line B4-2/55/17(1)/13 was generated and char-
acterized as previously described (Petrie et al., 1984) and was a
kind gift from Dr. Harry Greenberg (Stanford University
Medical School).
Antibodies
Rabbit polyclonal antiserum to the SA11 NSP4 synthetic
peptide aa113–149 (αNSP4113–149) was kindly provided by
Dr. Judy Ball (Texas A&M) (Parr et al., 2006). For mouse
αNSP4-FL, PCR-amplified fragments corresponding to SA11
NSP4 amino acids 1–175 were cloned into pFastBacHT (In-
vitrogen Corporation, Carlsbad, CA). Generation of the re-
combinant baculovirus and expression of HisNSP4-FL was
done as previously described (Zhang et al., 1998). HisNSP4-
FL was purified as described for bacterially expressed
HisNSP4 except N-lauroylsarcosine was used in place of
Triton-X100. The purity of HisNSP4-FL was determined by
SDS-PAGE followed by Coomassie Blue staining and the
concentration determined by the Bradford assay. Balb/C mice
were primed with 30 μg HisNSP4-FL per mouse in Freund's
complete adjuvant followed by 3 boosts of 10 μg/mouse in
Freund's incomplete adjuvant. The anti-NSP4 titers were de-
termined by ELISA. The antisera for the peptide specific
antibodies αNSP4114–135 and αNSP4120–147 were generated
as described previously (Ball et al., 1996), and antisera for the
peptide specific αNSP4150–175 was generated similarly. The
MAb B4-2/55/17(1)/13 hybridoma cell line was used to
generate ascites in pristine-primed Balb/C mice as previously
described (Burns et al., 1988).
Cloning of HisNSP4 truncation constructs
A 6×-histidine tag bacterial expression vector, pET46Ek/
LIC (EMD Biosciences, Inc., San Diego), was used to express
N- and C-terminal NSP4 deletion mutants. The primers used to
generate these constructs are listed in Table 1. PCR-amplified
fragments of NSP4 were generated using the appropriate
primer pairs and cloned into pET46Ek/LIC by ligation in-
dependent cloning according to the manufacturer's protocol.
Recombinant vector was transformed into competent BL21
(DE3) E. coli (EMD Biosciences, Inc., San Diego) and platedon LB agar supplemented with 100 μg/mL ampicillin. All
constructs were confirmed by nucleotide sequencing (Lone
Star Labs, Houston, TX).
Site-directed mutagenesis of HisNSP490–175
The specified residues in HisNSP490–175 were altered using
the Quickchange XL site-directed mutagenesis kit (Stratagene,
La Jolla, CA), using the primer pairs listed in Table 2, according
to the manufacturer's instructions. Briefly, the primer pairs
listed below containing the desired mutation were annealed to
the complementary regions of the parental plasmid template and
extended using Pfu polymerase to generate a mutated plasmid
containing staggered nicks. The methylated parental DNA was
digested by treatment with DpnI, and the newly synthesized
nicked vector DNA was used to transform competent BL21
(DE3) E. coli bacterial cells. Successful mutation of the desired
residue was validated by nucleotide sequencing.
Expression and purification of HisNSP4 truncation and mutant
constructs
Overnight cultures of BL21(DE3) cells transformed with each
plasmid were diluted to a ratio of 1:10 in fresh LB broth sup-
plemented with 100 μg/mL ampicillin. Cells were grown at 37 °C
for 3 h or until a cell density of A600=0.6–0.7 was reached.
Recombinant protein expression was induced by addition of
1.0 mM isopropyl-β-D-thiogalactopyranoside (IPTG) (Invitrogen
Corporation, Carlsbad, CA), and cultures were grown overnight
at 25 °C. Cells were harvested by centrifugation for 15 min at
13,800×g at 4 °C, and the cell pellet was suspended in lysis buffer
(10 mM sodium phosphate, 500 mM sodium chloride, 10 mM
imidazole, and 1% Triton X-100, pH 8.0) and incubated for
15 min to lyse the cells. Insoluble material was pelleted by
Table 2
Mutagenesis primers for alanine point mutants
Mutation Forward sequence Reverse sequence
D100A 5′GATGAGATAGAAAAGCAAATGGCCAGAGTAGTCAAAGAAATGAGAC 5′GTCTCATTTCTTTGACTACTCTGGCCATTTGCTTTTCTATCTCATC
K104A 5′GCAAATGGACAGAGTAGTCGCAGAAATGAGACGCCAGCTAG 5′CTAGCTGGCGTCTCATTTCTGCGACTACTCTGTCCATTTGC
E105A 5′CAAATGGACAGAGTAGTCAAAGCAATGAGACGCCAGCTAGAAATG 5′CATTTCTAGCTGGCGTCTCATTGCTTTGACTACTCTGTCCATTTG
R107A 5′GACAGAGTAGTCAAAGAAATGGCACGCCAGCTAGAAATGATTGAC 5′GTCAATCATTTCTAGCTGGCGTGCCATTTCTTTGACTACTCTGTC
R108A 5′CAGAGTAGTCAAAGAAATGAGAGCCCAGCTAGAAATGATTGACAAATTG 5′CAATTTGTCAATCATTTCTAGCTGGGCTCTCATTTCTTTGACTACTCTG
E111A 5′GTCAAAGAAATGAGACGCCAGCTAGCAATGATTGACAAATTGACTACACG 5′CGTGTAGTCAATTTGTCAATCATTGCTAGCTGGCGTCTCATTTCTTTGAC
M112A 5′GTCAAAGAAATGAGACGCCAGCTAGAAGCGATTGACAAATTGACTACACG 5′CGTGTAGTCAATTTGTCAATCGCTTCTAGCTGGCGTCTCATTTCTTTGAC
E105A/R108A/E111A 5′GGACAGAGTAGTCAAAGCAATGAGAGCCCAGCTAGCAATGATTGACAAATTG 5′CAATTTGTCAATCATTGCTAGCTGGGCTCTCATTGCTTTGACTACTCTGTCC
T117A/T118A 5′CTAGAAATGATTGACAAATTGGCCGCACGTGAAATTGAACAAGTAGAG 5′CTCTACTTGTTCAATTTCACGTGCGGCCAATTTGTCAATCATTTCTAG
R119A 5′GATTGACAAATTGACTACAGCTGAAATTGAACAAGTAGAG 5′CTCTACTTGTTCAATTTCAGCTGTAGTCAATTTGTCAATC
E120A 5′GACAAATTGACTACACGTGCAATTGAACAAGTAGAGTTG 5′CAACTCTACTTGTTCAATTGCACGTGTAGTCAATTTGTC
E122A 5′GACTACACGTGAAATTGCAGAACAAGTAGAGTTGC 5′GCAACTCTACTTGTTCTGCAATTTCACGTGTAGTC
Q123A 5′GACTACACGTGAAATTGAAGCTGTAGAGTTGCTTAAACGC 5′GCGTTTAAGCAACTCTACAGCTTCAATTTCACGTGTAGTC
L126A/L127A 5′CGTGAAATTGAACAAGTAGAGGCGGCCAAACGCATTTACGATAAATTG 5′CAATTTATCGTAAATGCGTTTGGCCGCCTCTACTTGTTCAATTTCACG
Y131A 5′GTAGAGTTGCTTAAACGCATTGCAGATAAATTGACGGTGCAAACG 5′CGTTTGCACCGTCAATTTATCTGCAATGCGTTTAAGCAACTCTAC
T135A 5′CGCATTTACGATAAATTGGCGGTGCAAACGACAGGCGAAATAG 5′CTATTTCGCCTGTCGTTTGCACCGCCAATTTATCGTAAATGCG
Q137A 5′CGATAAATTGACGGTGGCAACGACAGGCGAAATAG 5′CTATTTCGCCTGTCGTTGCCACCGTCAATTTATCG
T138A 5′CGATAAATTGACGGTGCAAGCGACAGGCGAAATAGATATGAC 5′GTCATATCTATTTCGCCTGTCGCTTGCACCGTCAATTTATCG
E160A 5′GTGAGAACGCTAGAAGAATGGGCAAGTGGAAAAAATCCTTATG 5′CATAAGGATTTTTTCCACTTGCCCATTCTTCTAGCGTTCTCAC
K163A 5′GAAGAATGGGAAAGTGGAGCAAATCCTTATGAACCAAGAG 5′CTCTTGGTTCATAAGGATTTGCTCCACTTTCCCATTCTTC
E170A 5′GGAAAAAATCCTTATGAACCAAGAGCAGTGACTGCAGCAATG 5′CATTGCTGCAGTCACTGCTCTTGGTTCATAAGGATTTTTTCC
The amino acid position of the mutation(s) is listed on the left with the corresponding forward and reverse primers.
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226 J.M. Hyser et al. / Virology 373 (2008) 211–228centrifugation for 30 min at 21,000×g at 4 °C. The supernatant
was reserved and the pellet was re-extracted with lysis buffer two
additional times. PBS-washed Ni2+–NTA beads (GE Healthcare
Bio-Sciences Corp., Piscataway, NJ) were added to the pooled
supernatants and incubated with agitation for 1 h at room
temperature. The Ni2+–NTA beads were pelleted by centrifu-
gation for 5 min at 3200×g at 4 °C, washed with wash buffer 1
(10 mM sodium phosphate, 500 mM sodium chloride, 10 mM
imidazole, pH 8.0), repelleted, and washed with wash buffer 2
(10 mM sodium phosphate, 500 mM sodium chloride, 50 mM
imidazole, pH 8.0). The beads were again pelleted and the
recombinant HisNSP4 proteins were eluted with elution buf-
fer (10 mM sodium phosphate, 500 mM sodium chloride,
500 mM imidazole, pH 8.0). Each recombinant protein was
characterized by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) according to a modified Laemmli
protocol (Zhang et al., 2000) followed by Coomassie Blue
(Sigma-Aldrich, St. Louis, MO) staining and protein concen-
tration was determined by the Bradford assay (Bio-Rad Lab-
oratories, Hercules, CA).
Immunoblot analysis of RV-infected cell lysates and HisNSP4
constructs
Cell lysates or purified HisNSP4 protein was mixed with
SDS-PAGE sample buffer, boiled for 5 min, and loaded onto 4–
20% polyacryamide gradient gels (BioRad) to separate protein
samples, which were then transferred onto a nitrocellulose
membrane (GE Healthcare Bio-Sciences Corp., Piscataway, NJ)
as previously described (Zhang et al., 2000). Nitrocellulose
membranes were stained with Ponceau S (Sigma-Aldrich, St.
Louis, MO) to confirm equal loading of protein. Membranes
were blocked using 5% Carnation Instant Milk in PBS (Blotto)
for 10 min with agitation at room temperature. Proteins were
detected with αNSP4113–149 serum at a dilution of 1:2000,
αNSP4-FL serum at a dilution of 1:1000, MAb B4-2/55/17(1)/
13 (B4-2/55) ascites at a dilution of 1:1000, αNSP4114–135 serum
at a dilution of 1:10,000, αNSP4120–147 serum at a dilution of
1:10,000, and αNSP4150–175 serum at a dilution of 1:10,000 in
0.5% Blotto. Alkaline phosphatase conjugated secondary anti-
bodies (Sigma-Aldrich, St. Louis, MO) were used at a dilution of
1:3000 in 0.5% Blotto. Membranes were incubated with the
primary antibodies at room temperature overnight, washed 3
times for 5 min in 0.5% Blotto, and incubated with the secondary
antibodies for approximately 2 h. The membranes were again
washed 3 times for 5 min in 0.5% Blotto and were developed
using alkaline phosphatase (AP) detection solution (50 mM Tris,
3 mM MgCl2, 0.1 mg/mL p-nitro blue tetrazolium chloride, and
0.05 mg/mL 5-bromo-4-chloro-3-indolyl phosphate).
Dot blot
Five micrograms of SA11 NSP4 peptides, aa113–149,
aa114–135, aa120–147 in 5 ul of 50 mM acetic acid, were
separately spotted onto a nitrocellulose membrane that was then
blocked with 3% Blotto. The peptides were detected with
αNSP4114–135 or αNSP4120–147 sera at a dilution of 1:15,000 in0.5% Blotto. Antibody-reactive dots were visualized with goat
anti rabbit IgG(L+H)-alkaline phosphatase conjugate and the
AP detection solution (as above).
Tris–Tricine gel electrophoresis and immunoblots of synthesized
NSP4 peptides
Synthesized NSP4 peptide aa128–142 of virus strains SA11
(3 μg) or S2 (18 ug), and their mutants Q137R (9 μg), T135I/
T138S (6 μg), T138S (6 μg), and T135I (6 μg) were resolved by
SDS-PAGE on a 16.5% Tris–Tricine gel (BioRad Laboratories
Tris–tricine system) and transferred onto a nitrocellulose
membrane that was then blocked with 3% Blotto (see Fig. 6
for peptide sequences). Approximately 15 μg of synthesized
SA11 NSP4 peptides aa150–165, aa155–170 and aa160–175
and their mutants were similarly resolved, transferred onto a
nitrocellulose membrane and blocked with 3% Blotto (see Fig. 7
for peptide sequences). The blocked membrane was detected
with αNSP4120–147 or αNSP4150–175 at a dilution of 1:5,000 in
PBS containing 1% BSA and 1% glycerol for 72 h at 4 °C, then
visualized with goat anti rabbit IgG(L+H)-alkaline phosphatase
conjugate developed with AP substrate.
MAb B4-2/55 End-point Titer ELISA
Purified wild-type or mutant NSP490–175 was coated onto
flat-bottomed polyvinylchloride 96-well microtiter plates
(Dynatech Laboratories, Inc., Alexandria, VA) at 10 μg/mL in
carbonate/bicarbonate solution, pH 9.6 (CBC) overnight at
4 °C. The plates were blocked with 5% Blotto for 1 h and then
washed 3 times with PBS–0.05% Tween 20. MAb B4-2/55 or
αNSP4-FL was diluted 1:50 in 0.5% Blotto, added to the
appropriate wells of the microtiter plate, diluted 2-fold down the
plate, and incubated for 1 h. The plates were again washed with
PBS-Tween. HRP-conjugated rabbit anti-mouse antibody was
diluted 1:1000 in 0.5% Blotto, added to the plates and incubated
for 1 h. After another wash, TMB substrate (K&PL, Gaithers-
burg, MD) was added, allowed to develop for 10 min before the
reaction was stopped with 1 M H3PO4. Absorbance at 405 nm
was measured using a Thermomax microplate reader (Mole-
cular Devices Corp., Menlo Park, CA). End-point titers were
determined to be the reciprocal of the last positive dilution. The
cut-off optical density (OD) was 0.096, which was calculated as
the mean of the OD of the blank plus 3 standard deviations. All
steps were carried out at room temperature.
Surface Plasmon Resonance (SPR) analysis of interactions
between NSP4 proteins and peptides binding to VP5⁎ or VP8⁎
SPR analysis was performed at 25 °C in a BIAcore 3000
system using an NTA sensor chip (BIAcore AB, Uppsala,
Sweden). Briefly, baculovirus expressed and purified 5×HisVP5⁎
or bacterially expressed and purified 6×HisVP8⁎ was immobi-
lized onto Ni2+ activated NTA sensor surface of flow cells up to
4500 resonance units (RU) on a BIAcore NTA sensor chip. For
the blank control, one of the flow cells on the sensor chip lacked
immobilized protein. Non-specific binding of the Ni2+-activated
227J.M. Hyser et al. / Virology 373 (2008) 211–228sensor surface of flow cells was blocked by BSA in HEPES-
buffered saline (HBS: 10 mM HEPES, 150 mM NaCl, 50 μM
EDTA, 0.005% Surfactant P20, pH 7.4). Recombinant SA11
NSP4-FL in HBS containing 1 mMMgCl2 was injected into the
flow cells of the NTA sensor chip at a flow rate of 5 μl/min. The
binding RU of NSP4 proteins to VP5⁎ or VP8⁎were obtained by
subtraction of the RU of the blank control from the RU of the
reaction flow cells. Additionally, HisVP5⁎ was covalently
immobilized onto the sensor surface on a BIAcore CM5 sensor
chip, according to the manufacturer's protocol. Synthetic NSP4
peptides aa114–135 and aa150–175 in HBS were injected as
above. Based on the correlation between the SPR response and
change in soluble protein and peptide binding to the immobilized
protein, values for the binding ratio, Vbound, and the concentration
of free protein, [P]free, were calculated using equations described
previously (Rich et al., 1999). The KD of NSP4-FL and NSP4
peptide aa114–135 for VP5⁎ was calculated using a one-site-
binding nonlinear regression model.
NSP4–VP5⁎ binding and antibody blocking ELISA
Microtiter wells (Dynex Technologies) were coated with 1 μg
of purified recombinant 5×HisVP5⁎ in CBC containing 1 mM
MgCl2 overnight. The wells were washed with Tris buffered
saline+1mMMgCl2 (TBS) and incubated with blocking solution
(TBS containing 1%, w/v, BSA and 0.05%, v/v, Tween 20) for
1 h. Varying concentrations of the NSP4 peptide-specific anti-
serum, rabbit pre-immune serum, or no antibody as a positive
control were combined with either 1 μg of purified recombinant
SA11 HisNSP4-FL in TBS or buffer alone as a negative control
and added to the wells. After incubation overnight, the wells were
washedwith TBS+0.05%Tween 20 (TBS-T).MouseαNSP4-FL
antiserum, diluted 1:3000, in TBS-T+2.5% normal rabbit serum
was added to the wells. After incubation for 1 h, the wells were
washed and HRP-conjugated rabbit anti-mouse antibody diluted
1:3000 in TBS-T+2.5% normal rabbit serum was added to the
wells. After incubation for 1 h, the wells were again washed and
developed as described above. Background was calculated as the
mean OD plus 3 standard deviations of the negative control (no
NSP4 added), and NSP4 binding to VP5⁎ in the presence of the
blocking antisera is presented as the percent of the positive
control. All steps were carried out at room temperature.
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